Learn More
e19002 Background: SAiL is an ongoing, multicenter, international, open-label trial investigating the safety and efficacy of first-line Bv in combination with a range of standard first-line(More)
7035 Background: Second-line treatment for NSCLC patients (pts) with good performance status improves survival. Using the recent trial comparing survival with pemetrexed (500 mg/m2 q3wks) vs(More)